Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future
Live Q&A
Date
22 Nov 2020Session
Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the FuturePresenters
Hiroshi TanakaAuthors
B.C. Cho1, J.W. Chang2, H. Tanaka3Author affiliations
- 1 Yonsei Cancer Center, Yonsei University College of Medicine, Seoul/KR
- 2 Medical Oncology, Chang Gung Medical Foundation–Linkou, Taoyuan/TW
- 3 Department Of Internal Medicine, Niigata Cancer Center Hospital, Niigata/JP
Resources
Resources from the same session
Introduction
Presenter: Byoung Cho
Session: Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future
Resources:
Webcast
Navigating first-line treatment decisions for EGFRM+ NSCLC: Extrapolating from Asian clinical trial experience
Presenter: John Wen-Cheng Chang
Session: Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future
Resources:
Webcast
Tackling Uncommon EGFR mutations: Efficacy of EGFR TKIs in NSCLC
Presenter: Hiroshi Tanaka
Session: Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future
Resources:
Webcast
KRAS-mutant NSCLC treatment advances on the horizon
Presenter: Byoung Cho
Session: Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future
Resources:
Webcast
Closing
Presenter: Byoung Cho
Session: Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future
Resources:
Webcast